Associated Papers
HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
Kekeeva T et al.
International Journal of Molecular Sciences, 2023
37445679 (PubMed )
Supplement: ijms-24-10497-s001.zip › ijms-2442047-supplementary.xlsx › ____1
A spectrum of BRCA1 and BRCA2 germline deleterious variants in ovarian cancer in Russia.
Kechin A et al.
Breast Cancer Research and Treatment, 2023
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Dev H et al.
Nature Cell Biology, 2018
30022119 (PubMed )
Supplement: NIHMS78112-supplement-Supplementary_table_5.xlsx › Fig_7b
Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X et al.
Familial Cancer, 2017
Select a paper to view details